| Literature DB >> 35078822 |
Anson Dong1, Christopher Meaney2, Gurbani Sandhu2, Nelia De Oliveira2, Suzanne Singh2, Natalie Morson2, Milena Forte2.
Abstract
BACKGROUND: There has been concern about declining routine vaccination rates during the COVID-19 pandemic. We evaluated the impact of the COVID-19 pandemic on early childhood vaccination rates at 2 sites of an academic family health team in the Greater Toronto Area, Ontario, serving both an urban and suburban patient population.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35078822 PMCID: PMC8920592 DOI: 10.9778/cmajo.20210084
Source DB: PubMed Journal: CMAJ Open ISSN: 2291-0026
Vaccine-eligible patients in the pre-COVID-19 (Jan. 1, 2018, to Mar. 16, 2020) and COVID-19 (Mar. 17, 2020, to Nov. 30, 2020) groups based on age for selected childhood vaccinations6
| Age and vaccination | Birth date interval | No. of patients | |||
|---|---|---|---|---|---|
|
|
| ||||
| Pre-COVID-19 group | COVID-19 group | Eligible in pre-COVID-19 period | Eligible in COVID-19 period | Ineligible | |
| 2 mo, DTaP-IPV-Hib | Jan. 1, 2018 to Jan. 17, 2020 | Jan. 17, 2020 to Aug. 31 2020 | 375 | 131 | 0 |
|
| |||||
| 2 mo, Pneu-C-13 | Jan. 1, 2018 to Jan. 17, 2020 | Jan. 17, 2020 to Aug. 31, 2020 | 375 | 131 | 0 |
|
| |||||
| 4 mo, DTaP-IPV-Hib | Jan. 1, 2018 to Nov. 17, 2019 | Nov. 17, 2019 to June 30, 2020 | 348 | 124 | 34 |
|
| |||||
| 4 mo, Pneu-C-13 | Jan. 1, 2018 to Nov. 17, 2019 | Nov. 17, 2019 to June 30, 2020 | 348 | 124 | 34 |
|
| |||||
| 6 mo, DTaP-IPV-Hib | Jan. 1, 2018 to Sept.17, 2019 | Sept. 17, 2019 to Apr. 30, 2020 | 315 | 121 | 70 |
|
| |||||
| 12 mo, MMR | Jan. 1, 2018 to Mar. 17, 2019 | Mar. 17, 2019 to Oct. 31, 2019 | 214 | 127 | 165 |
|
| |||||
| 12 mo, Pneu-C-13 | Jan. 1, 2018 to Mar. 17, 2019 | Mar. 17, 2019 to Oct. 31, 2019 | 214 | 127 | 165 |
|
| |||||
| 12 mo, Men-C-C | Jan. 1, 2018 to Mar. 17, 2019 | Mar. 17, 2019 to Oct. 31, 2019 | 214 | 127 | 165 |
|
| |||||
| 15 mo, Var | Jan. 1, 2018 to Dec.17, 2018 | Dec. 17, 2018 to July 31, 2019 | 175 | 99 | 232 |
|
| |||||
| 18 mo, DTaP-IPV-Hib | Jan. 1, 2018 to Sept.17, 2018 | Sept.17, 2018 to Apr. 31, 2019 | 129 | 104 | 273 |
Note: DTap-IPV-Hib = diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type B; Men-C-C = meningococcal conjugate C; MMR = measles, mumps, rubella; Pneu-C-13 = pneumococcal conjugate 13; Var = varicella.
Characteristics of study participants, born between Jan. 1, 2018, and Aug. 31, 2020, with at least 1 vaccination
| Characteristic | No. (%) of participants |
|---|---|
| Sex | |
| Male | 265 (52.4) |
| Female | 241(47.6) |
| Age, mo | |
| Mean | 18.5 |
| Median (IQR) | 17.7 (10.0–26.6) |
| Birth date, range | Jan. 1, 2018 to Aug. 29, 2020 |
| Regional income | |
| Low | 127 (25.1) |
| Middle | 291 (57.5) |
| High | 127 (25.1) |
| Missing | 3 (0.6) |
| Regional ethnic density | |
| Low | 89 (17.6) |
| Middle | 267 (52.8) |
| High | 140 (27.7) |
| Missing | 10 (1.9) |
Note: IQR = interquartile range.
Unless indicated otherwise.
As determined using postal code information.
Density of visible minorities as compared with national average.
Proportion of patients receiving timely, delayed or no vaccination in the pre-COVID-19 (Jan. 1, 2018, to Mar. 16, 2020) and COVID-19 (Mar. 17, 2020, to Nov. 30, 2020) periods
| Age and vaccination | Pre-COVID-19 | COVID-19 | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
| No. of eligible patients | No. (%, CI) vaccinated on time | No. (%, CI) delayed vaccination | No. (%, CI) not vaccinated | No. of eligible patients | No. (%, CI) vaccinated on time | No. (%, CI) delayed vaccination | No. (%, CI) not vaccinated | ||
| 2 mo, DTaP-IPV-Hib | 375 | 355 (94.67, 91.88–96.71) | 14 (3.73, 2.06–6.18) | 6 (1.60, 0.59–3.45) | 131 | 124 (94.66, 89.30–97.82) | 6 (4.58, 1.70–9.70) | 1 (0.76, 0.02–4.18) | 0.7586 |
|
| |||||||||
| 2 mo, Pneu-C-13 | 375 | 352 (93.87, 90.94–96.07) | 13 (3.47, 1.86–5.86) | 10 (2.67, (1.29–4.85) | 131 | 124 (94.66, 89.30–97.82) | 6 (4.58, 1.70–9.70) | 1 (0.76, 0.02–4.18) | 0.3913 |
|
| |||||||||
| 4 mo, DTaP-IPV-Hib | 330 | 310 (93.94, 90.79–96.26) | 18 (5.45, 3.26–8.48) | 2 (0.61, 0.07–2.17) | 116 | 113 (97.41, 92.63–99.46) | 2 (1.72, 0.21–6.09) | 1 (0.86, 0.02–4.71) | 0.1811 |
|
| |||||||||
| 4 mo, Pneu-C-13 | 328 | 311 (94.82, 91.83–96.95) | 16 (4.88, 2.81–7.80) | 1 (0.30, (0.01–1.69) | 115 | 111 (96.52, 91.33–99.04) | 2 (1.74, 0.21–6.14) | 2 (1.74, 0.21–6.14) | 0.0875 |
|
| |||||||||
| 6 mo, DTaP-IPV-Hib | 280 | 259 (92.50, 88.76–95.30) | 19 (6.79, 4.13–10.39) | 2 (0.71, 0.09–2.56) | 108 | 93 (86.11, 78.13–92.01) | 10 (9.26 (4.53–16.37) | 5 (4.63, 1.52–10.47) | 0.024 |
|
| |||||||||
| 12 mo, MMR | 214 | 174 (81.31, 75.43–86.30) | 27 (12.62, 8.48–17.82) | 13 (6.07, 3.27–10.16) | 127 | 88 (69.29, 60.49–77.17) | 24 (18.90, 12.50–26.80) | 15 (11.81, 6.76–18.73) | 0.0321 |
|
| |||||||||
| 12 mo, Pneu-C-13 | 188 | 160 (85.11, 79.20–89.87) | 20 (10.64, 6.62–15.95) | 8 (4.26, 1.85–8.21) | 117 | 84 (71.79, 62.73–79.72) | 21 (17.95, 11.47–26.12) | 12 (10.26, 5.41–17.23) | 0.0148 |
|
| |||||||||
| 12 mo, Men-C-C | 214 | 173 (80.84, 74.92–85.89) | 29 (13.55, 9.27–18.88) | 12 (5.61, 2.93–9.59) | 127 | 84 (66.14, 57.21–74.30) | 26 (20.47, 13.83–28.54) | 17 (13.39, 8.00–20.56) | 0.0063 |
|
| |||||||||
| 15 mo, Var | 175 | 112 (64.00, 56.41–71.10) | 43 (24.57, 18.39–31.64) | 20 (11.43, 7.12–17.10) | 99 | 52 (52.53, 42.24–62.66) | 24 (24.24, 16.19–33.89) | 23 (23.23, 15.33–32.79) | 0.0324 |
|
| |||||||||
| 18 mo, DTaP-IPV-Hib | 100 | 73 (73.00, 63.20–81.39) | 20 (20.00, 12.67–29.18) | 7 (7.00, 2.86–13.89) | 91 | 56 (61.54, 50.75–71.55) | 23 (25.27, 16.75–35.47) | 12 (13.19, 7.00–21.90) | 0.1969 |
Note: CI = confidence interval; DTaP-IPV-Hib = diphtheria, tetanus, acellular pertussis, inactivated polio vaccine Haemophilus influenzae type B; Men-C-C = meningococcal conjugate C; MMR = measles, mumps, rubella; Pneu-C-13 = pneumococcal conjugate 13; Var = varicella.
Calculated using Fisher exact test to assess changes in vaccination uptake pre-COVID-19 versus during COVID-19.
Median time to vaccination for each of the routine childhood vaccinations in the pre-COVID-19 (Jan. 1, 2018, to Mar. 16, 2020) and COVID-19 (Mar. 17 to Nov. 30, 2020) periods
| Age and vaccination | Pre-COVID-19 | COVID-19 | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| No. of eligible patients | No. of vaccinations | Median (95% CI) time to vaccination, mo | No. of eligible patients | No. of vaccinations | Median (95% CI) time to vaccination, mo | ||
| 2 mo, DTaP-IPV-Hib | 375 | 369 | 2.07 (2.07–2.10) | 131 | 130 | 2.10 (2.07–2.14) | 0.9453 |
|
| |||||||
| 2 mo, Pneu-C-13 | 375 | 365 | 2.07 (2.07–2.10) | 131 | 130 | 2.10 (2.07–2.14) | 0.9452 |
|
| |||||||
| 4 mo, DTaP-IPV-Hib | 330 | 328 | 4.14 (4.14–4.18) | 116 | 115 | 4.14 (4.11–4.21) | 0.4203 |
|
| |||||||
| 4 mo, Pneu-C-13 | 328 | 327 | 4.14 (4.14–4.18) | 115 | 113 | 4.14 (4.11–4.21) | 0.4794 |
|
| |||||||
| 6 mo, DTaP-IPV-Hib | 280 | 278 | 6.18 (6.15–6.21) | 108 | 103 | 6.25 (6.18–6.35) | 0.0054 |
|
| |||||||
| 12 mo, MMR | 214 | 201 | 12.2 (12.2–12.3) | 127 | 112 | 12.3 (12.2–12.4) | 0.0534 |
|
| |||||||
| 12 mo, Pneu-C-13 | 188 | 180 | 12.3 (12.2–12.4) | 117 | 105 | 12.3 (12.2–12.4) | 0.0892 |
|
| |||||||
| 12 mo, Men-C-C | 214 | 202 | 12.3 (12.2–12.4) | 127 | 110 | 12.4 (12.3–12.5) | 0.0072 |
|
| |||||||
| 15 mo, Var | 175 | 155 | 15.5 (15.3–15.7) | 99 | 76 | 15.7 (15.5–17.3) | 0.0391 |
|
| |||||||
| 18 mo, DTaP-IPV-Hib | 100 | 93 | 18.4 (18.2–18.6) | 91 | 79 | 18.6 (18.4–18.9) | 0.1093 |
Note: CI = confidence interval; DTaP-IPV-Hib = diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B; Men-C-C = meningococcal conjugate C; MMR = measles, mumps, rubella; Pneu-C-13 = pneumococcal conjugate 13; Var = varicella.
Calculated using Kaplan–Meier test to assess differences in each of the routine childhood vaccination’s cumulative incidence functions pre-COVID-19 versus during COVID-19.